Creabilis
Creabilis is an emerging European specialty pharmaceutical company specializing in dermatology and focused on developing innovative treatments for skin disorders. The company is committed to addressing significant unmet medical needs in this area and has a strong track record in dermatological research. Creabilis has established a robust pipeline of clinical and pre-clinical drug candidates, including its lead product, CT327, which is a topical treatment for chronic pruritus and is set to enter Phase II clinical trials. Additionally, the company plans to build a pruritus franchise around CT327 and another candidate, CT340, both of which were developed using its proprietary Low Systemic Exposure platform technology. Through its innovative drug discovery programs, Creabilis aims to market these products directly or in partnership, reinforcing its position in the specialty pharmaceuticals sector.
Nautilus Biotech
Venture Round in 2007
Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.